Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Oct 9;27(19):6722. doi: 10.3390/molecules27196722

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Effect of 10 weeks of repeated dose treatment of SA on (A) cardiac hypertrophic index, and (B) cardiac hypertrophic parameters in rats with nSTZ-induced T2DM at the end of the 18th week. Data are expressed as mean ± SD, where n = 6 rats per group; A (p < 0.05), B (p < 0.01), and C (p < 0.001) indicate a significant difference from the normal control; a (p < 0.05), b (p < 0.01), and d (p < 0.001) indicate a significant difference from the diabetic control; and 1 (p < 0.05), 2 (p < 0.01), and 3 (p < 0.001) indicate a significant difference from the metformin-treated group.

Effect of 10 weeks of repeated dose treatment of SA on (A) cardiac hypertrophic index, and (B) cardiac hypertrophic parameters in rats with nSTZ-induced T2DM at the end of the 18th week. Data are expressed as mean ± SD, where n = 6 rats per group; A (p < 0.05), B (p < 0.01), and C (p < 0.001) indicate a significant difference from the normal control; a (p < 0.05), b (p < 0.01), and d (p < 0.001) indicate a significant difference from the diabetic control; and 1 (p < 0.05), 2 (p < 0.01), and 3 (p < 0.001) indicate a significant difference from the metformin-treated group.